Health Care

Stocks in Concentration: CytRx Corporation (NASDAQ:CYTR), Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

0 30

CytRx Corporation (NASDAQ:CYTR) went lower by -8.275% to close at $ 0.899. The company exchanged total volume of 7.19 million shares throughout course of last trade however it holds an average trading capacity of 1.76 million shares. Shares of company began trading at $0.980 climbed to high of $0.980 touched the low of $0.850.

The company is trading below its 50-day moving averages of 2.311 and down from 200-day moving averages of 2.492. The firm has price to book ratio of 1.945 and its price to sale ratio was 654.315.

CytRx Corporation (CYTR), a biopharmaceutical research and development firmspecializing in oncology recently reported a proposed registered public offering of its ordinary stock and one year warrants to purchase ordinary stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as exclusive placement agent for the offering.

CytRx Corporation’s (CYTR) has price-to-cash ratio of 0.86 and price to sale ratio of 589.56. . A look on the firm performance, its monthly performance is -60.74% and a quarterly performance of -71.28%. The stock price is moving down from its 20 days moving average with -58.52% and isolated negatively from 50 days moving average with -63.56%.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. One week ago, shares have been suggested as “BUY” from “1” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1.67” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) surged +1.50% and closed the trade at $ 8.81. The company recorded a trading capacity of 1.01 million shares below its three months average daily volume of 1.68 million shares. During the last trade, shares reached to high price of $9.00 and touched the low price of $8.55. The stock’s 50-day moving average is noted at $10.10 and its 200-day moving average is stands at $8.33.

Additionally, the company has EPS of -0.38. The company has market capitalization of $643.98M.

The average true range of Inovio Pharmaceuticals, Inc.’s (INO) is recorded at 0.47 and the relative strength index of the stock stands 39.60. The stock price is going above to its 52 week low with 95.78% and lagging behind from its 52 week high with -24.64%. Analyst recommendation for this stock stands at 1.60. A look on the firm performance, its monthly performance is -14.22% and a quarterly performance of -7.56%. The stock price is trading upbeat from its 200 days moving average with 13.28% and down from 50 days moving average with -12.51%.

Inovio Pharmaceuticals, Inc. (INO) reported that its novel DNA-based monoclonal antibody technology will be deployed to develop products which could be used alone and in combination with other immunotherapies in the pursuit of new ways to treat and potentially cure infection from the HIV virus.

 

In a recently published article, Inovio demonstrated that a single administration in mice of a highly optimized dMAb® DNA, which targets HIV, generated antibody molecules in the bloodstream that possessed desirable functional activity including high antigen-binding and HIV-neutralization capabilities against diverse strains of HIV viruses.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. One week ago, shares have been suggested as “BUY” from “0” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

 

 

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

Advirtisement

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter